← Evidence map

ArticleBiomaterials research2026

PD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3.

Seok-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

PD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3. | OpenQuestion